DRRDs operational performance has largely bottomed out in 1HFY17 and is likely to improve in quarters ahead. However, only in 2HFY18 will we see a full recovery in the US segment and at company level owing to several niche product approvals in the US, close out letters for the key facilities and better traction in Russia region. With two washout quarters behind us, FY17 numbers are likely to remain subdued and earnings growth will only be seen from FY18E on a favorable base.